This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

CloudMD Software & Services Valuation

Is DOCR.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DOCR.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DOCR.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DOCR.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DOCR.F?

Key metric: As DOCR.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DOCR.F. This is calculated by dividing DOCR.F's market cap by their current revenue.
What is DOCR.F's PS Ratio?
PS Ratio	0.1x
Sales	CA$90.82m
Market Cap	CA$10.66m

DOCR.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	-2.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does DOCR.F's PS Ratio compare to its peers?

The above table shows the PS ratio for DOCR.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.5x
PRPO Precipio	0.5x	n/a	US$8.8m
CMAX CareMax	0.004x	26.0%	US$2.7m
VVOS Vivos Therapeutics	1x	22.9%	US$15.2m
IDXG Interpace Biosciences	0.3x	n/a	US$11.7m
DOCR.F CloudMD Software & Services	0.1x	n/a	US$10.7m

Price-To-Sales vs Peers: DOCR.F is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.3x).

Price to Sales Ratio vs Industry

How does DOCR.F's PS Ratio compare vs other companies in the US Healthcare Industry?

31 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	1.1x	6.6%
DOCR.F CloudMD Software & Services	0.1x	n/a	US$7.82m
MCK McKesson	0.2x	8.1%	US$79.11b
CVS CVS Health	0.2x	4.6%	US$73.00b

31 Companies		Estimated Growth	Market Cap
Industry Avg.	1.1x	20.9%
DOCR.F CloudMD Software & Services	0.1x	n/a	US$7.82m

No more companies

Price-To-Sales vs Industry: DOCR.F is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is DOCR.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DOCR.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate DOCR.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

18.8%

27.5%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

0.5%

-15.7%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

16.2%

99.5%